Unexpected cases of severe liver disease in HIV-infected patients have been reported and an association with didanosine (ddI) has been suggested. Transient elastography (TE) might detect patients harbouring such a condition. Our objective was to search for the presence of abnormal liver stiffness (LS) in a cohort of HIV-infected patients without HBV or HCV coinfection and to assess the related factors.
Methods
A cross-sectional prospective study was conducted. LS was assessed by TE in 258 HIV-infected patients without HBV or HCV coinfection and with no evidence of acute hepatotoxicity or other origins of liver disease. LS values ≥7.2 kPa were considered abnormal. Multivariate analyses were performed to identify factors associated with abnormal LS.
Results
Abnormal LS was observed in 29 (11.2%) patients. A total of 18 (16.4%) patients previously treated with ddI and 11 (7.4%) of those who never received ddI had LS values ≥7.2 kPa (P=0.02). The prevalence of abnormal LS was higher in patients previously treated with abacavir than in those who had never received abacavir (15 [21.7%] versus 14 [7.4%]; P=0.001). After multivariate analyses, age (adjusted odds ratio [AOR] 1.05, 95% confidence interval [CI] 1.002-1.1; P=0.004) alcohol intake >50 g/day (AOR 7.2, 95% CI 2.6-19.7; P<0.0001), CD4+ T-cell count <200 cells/ml (AOR 3.4, 95% CI 1.06-11.007; P=0.03), time on ddI treatment (AOR 1.31, 95% CI 1.12-1.52; P=0.001) and previous abacavir exposure (AOR 3.01, 95% CI 1.18-7.67; P=0.02) were independently associated with abnormal LS.
Conclusions
The prevalence of abnormal LS in HIV-infected patients without HBV or HCV coinfection is substantial. Long-term exposure to ddI is a major cause of liver damage in these patients.
References
1.
PalellaF.J.Jr., DelaneyK.M., MoormanA.C.Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.N Engl J Med1998; 338: 853–860.
2.
The CASCADE Collaboration.Survival after introduction of HAART in people with known duration of HIV-1 infection.Lancet2000; 355: 1158–1159.
3.
PinedaJ.A., García-GarcíaJ.A., Aguilar-GuisadoM.Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy.Hepatology2007; 46: 622–630.
4.
The Data Collection on Adverse Events of Anti-HIV Drugs Study Group.Liver-related deaths in persons infected with HIV: the D:A:D study.Arch Intern Med2006; 166: 1632–1641.
5.
BicaI., McGovernB., DhazR.Increasing mortality due to end-stage liver disease in patients with HIV infection.Clin Infect Dis2001; 32: 492–497.
6.
RosenthalE., PoiréeM., PradierC.Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study).AIDS2003; 17: 1803–1809.
7.
MaidaI., NúñezM., RiosM.J.Severe liver disease associated with prolonged exposure to antiretroviral drugs.J Acquir Immune Defic Syndr2006; 42: 177–182.
8.
MaidaI., Garcia-GascoP., SotgiuG.Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome.Antivir Ther2008; 13: 103–107.
9.
SchianoT.D., KotlerD.P., FerranE., FielM.I.Hepatoportal sclerosis is a cause of noncirrhotic portal hypertension in patients with HIV.Am J Gastroenterol2007; 102: 2536–2540.
10.
MalletV., BlanchardP., VerkarreV.Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients.AIDS2007; 21: 187–192.
11.
GarveyL.J., ThomsonE.C., LloydJ., CookeG.S., GoldinR.D., MainJ.Response to Mallet, et al. ‘Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients’.AIDS2007; 21: 1494–1495.
12.
CasteraL., VergniolJ., FouvherJ.Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.Gastroenterology2005; 128: 343–350.
13.
ZiolM., Handra-LucaA., KettanehA.Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C.Hepatology2005; 41: 48–54.
14.
MarcellinP., ZiolM., BedossaP.Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B.Liver Int2009; 29: 242–247.
15.
CorpechotC., El NaggarA., Poujol-RobertA.Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC.Hepatology2006; 43: 1118–1124.
16.
YonedaM., FujitaK., InamoriM., NakajimaA., TamamoM., HiraishiH.Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD).Gut2007; 56: 1330–1331.
17.
Ganne-CarriéN., ZiolM., de LedinghenV.Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases.Hepatology2006; 44: 1511–1517.
18.
de LédinghenV., DouvinC., KettanehA.Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/Hepatitis C virus-coinfected patients.J Acquir Immune Defic Syndr2006; 41: 175–179.
19.
VergaraS., MacíasJ., RiveroA.The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection.Clin Infect Dis2007; 45: 969–974.
20.
MacíasJ., RecioE., VispoE.Application of transient elastometry to differentiate mild from moderate to severe liver fibrosis in HIV/HCV co-infected patients.J Hepatol2008; 49: 916–922.
21.
VizzuttiF., ArenaU., RomanelliR.G.Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis.Hepatology2007; 45: 1290–1297.
22.
CarrionJ.A., NavasaM., BoschJ., BrugueraM., GilabertR., FornsX.Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation.Liver Transpl2006; 12: 1791–1798.
23.
CasteraL., FornsX., AlbertiA.Non-invasive evaluation of liver fibrosis using transient elastography.J Hepatol2008; 48: 835–847.
24.
ScheuerP.J.Classification of chronic viral hepatitis: a need for reassessment.J Hepatol1991; 13: 372–374.
25.
WanlessI.R.Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2500 autopsies and a new classification of benign hepatocellular nodules.Hepatology1990; 11: 787–797.
26.
BenhamouY., MartinoV., BochetM.Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy.Hepatology2001; 34: 283–287.
27.
MohsenA.H., EasterbrookP.J., TaylorC.Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients.Gut2003; 52: 1035–1040.
28.
TuralC., FusterD., TorJ.Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients.J Viral Hepat2003; 10: 118–125.
29.
Martín-CarboneroL., BenhamouY., PuotiM.Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study.Clin Infect Dis2004; 38: 128–133.
30.
MacíasJ., CastellanoV., MerchanteN.Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine.AIDS2004; 18: 767–774.
31.
Mariné-BarjoanE., Saint-PaulM-C, PradierC.Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients.AIDS2004; 18: 2163–2170.
32.
MacíasJ., MiraJ.A., López-CortésL.F.Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C.Antivir Ther2006; 11: 839–846.
33.
LinW., WeinbergE.M., TaiA.W.HIV increases HCV replication in a TGF-beta1-dependent manner.Gastroenterology2008; 134: 803–811.
34.
KovariH., LedergerberB., PeterU.Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study.Clin Infect Dis2009; 49: 626–635.
De BruyneR., PortmannB., SamynM.Chronic liver disease related to 6-thioguanine in children with acute lymphoblastic leukaemia.J Hepatol2006; 44: 407–410.
37.
VoraA., MitchellC., LennardL.Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial.Lancet2006; 368: 1339–1348.
38.
D:A:D Study Group.Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.Lancet2008; 371: 1417–1426.
39.
The SMART/INSIGHT and the D:A:D Study Groups.Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.AIDS2008; 22: F17–F24.
40.
LangS., Mary-KrauseM., CotteL.Impact of specific NRTI and PI exposure on the risk of myocardial infarction: a case-control study nested within FHDH ANRS CO4.16th Conference on Retroviruses and Opportunistic Infections. 8–11 February 2009, Montreal, QC, Canada. Abstract 43LB.
41.
BrothersC.H., HernandezJ.E., CutrellA.G.Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects.J Acquir Immune Defic Syndr2009; 51: 20–28.
42.
BensonC., RibaudoH., ZhengE.No association of abacavir use with risk of myocardial infarction or severe cardiovascular disease events: results from ACTG A5001.16th Conference on Retroviruses and Opportunistic Infections. 8–11 February 2009, Montreal, QC, Canada. Abstract 721.
43.
FraquelliM., RigamontiC., CasazzaG.Reproducibility of transient elastography in the evolution of liver fibrosis in patients with chronic liver disease.Gut2007; 56: 968–973.
44.
NeukamK., RecioE., CamachoA.Interobserver concordance in the assessment of liver fibrosis in HIV/HCV-coinfected patients using transient elastometry.Eur J Gastroenterol Hepatol2010; 22: 801–807.
45.
RoulotD., CzernichowS., Le ClésiauH., CostesJ-L, VergnaudA-C, BeaugrandM.Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome.J Hepatol2008; 48: 606–613.
